Abstract
A dual approval process for cancer drugs and their corresponding genetic tests has fast-tracked patients' access to targeted cancer therapies in Australia. For the first time, one review process has been used to approve and list two lung cancer drugs—gefitinib and erlotinib—in the country's Pharmaceutical Benefits Scheme (PBS) and their corresponding genetic tests in the publication Medicare Benefits Schedule (MBS).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
